BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 2014;9:e100305. [PMID: 24945380 DOI: 10.1371/journal.pone.0100305] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 10.5] [Reference Citation Analysis]
2 Lock M, Meyers BM, Mujoomdar A. The addition of radiofrequency ablation for patients receiving sorafenib: new evidence for a new standard? Ann Transl Med 2021;9:3. [PMID: 33553296 DOI: 10.21037/atm-20-7474] [Reference Citation Analysis]
3 Parvinian A, Casadaban LC, Hauck ZZ, van Breemen RB, Gaba RC. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model. Diagn Interv Radiol 2015;21:235-40. [PMID: 25835078 DOI: 10.5152/dir.2014.14394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
4 Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N, Milicevic M. Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 2015;7:2274-2291. [PMID: 26380652 DOI: 10.4254/wjh.v7.i20.2274] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
5 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Kondo M, Numata K, Hara K, Nozaki A, Fukuda H, Chuma M, Maeda S, Tanaka K. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterol Res Pract 2017;2017:5728946. [PMID: 28717362 DOI: 10.1155/2017/5728946] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
7 Wang G, Liu Y, Zhou SF, Qiu P, Xu L, Wen P, Wen J, Xiao X. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review. Hepatol Int. 2016;10:501-510. [PMID: 26856326 DOI: 10.1007/s12072-015-9700-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
8 Yoon JS, Kim G, Lee YR, Park SY, Tak WY, Kweon YO, Park JG, Lee HW, Han YS, Ha HT, Chun JM, Jang SY, Hur K. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med 2018;12:1105-14. [PMID: 30191729 DOI: 10.2217/bmm-2018-0096] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
9 Lin J, Wu L, Bai X, Xie Y, Wang A, Zhang H, Yang X, Wan X, Lu X, Sang X, Zhao H. Combination treatment including targeted therapy for advanced hepatocellular carcinoma. Oncotarget 2016;7:71036-51. [PMID: 27626176 DOI: 10.18632/oncotarget.11954] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
10 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
11 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
12 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
13 Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma. BMC Cancer 2017;17:645. [PMID: 28899349 DOI: 10.1186/s12885-017-3545-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
14 Cao DD, Xu HL, Liu L, Zheng YF, Gao SF, Xu XM, Ge W. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:44976-93. [PMID: 28402958 DOI: 10.18632/oncotarget.16689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Van Leeuwen MT, Luu S, Gurney H, Brown MR, Pearson SA, Webber K, Hunt L, Hong S, Delaney GP, Vajdic CM. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. JNCI Cancer Spectr 2020;4:pkaa076. [PMID: 33392444 DOI: 10.1093/jncics/pkaa076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Wang Y, Benzina A, Molin DG, Akker NVD, Gagliardi M, Koole LH. Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy. Journal of Biomaterials Science, Polymer Edition 2014;26:77-91. [DOI: 10.1080/09205063.2014.982242] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
18 Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V, Deepashree T, Uthappa MC, Ilankumaran K, Govil S, Srinivas Reddy M, Rela M. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. Annals of Hepatology 2017;16:247-54. [DOI: 10.5604/16652681.1231585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
19 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016;22:5384-92. [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
20 Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015;19:23-43. [PMID: 25454295 DOI: 10.1016/j.cld.2014.09.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
21 Cai R, Song R, Pang P, Yan Y, Liao Y, Zhou C, Wang S, Zhou X, Wang H, Zhang H, Sun H, Ma H. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis. BMC Cancer 2017;17:714. [PMID: 29110700 DOI: 10.1186/s12885-017-3707-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: an Eastern perspective. World J Gastroenterol. 2015;21:3826-3842. [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
23 Chen A, Li S, Yao Z, Hu J, Cao J, Topatana W, Juengpanich S, Yu H, Shen J, Chen M. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis. J Gastroenterol Hepatol 2021;36:302-10. [PMID: 32652685 DOI: 10.1111/jgh.15180] [Reference Citation Analysis]
24 Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, Kochi T, Suetsugu A, Shiraki M, Shimizu M. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib. Int J Mol Sci. 2015;16:9612-9624. [PMID: 25927582 DOI: 10.3390/ijms16059612] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
25 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
26 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015;7:2009-2019. [PMID: 26261690 DOI: 10.4254/wjh.v7.i16.2009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
27 Tam AL, Melancon MP, Abdelsalam M, Figueira TA, Dixon K, McWatters A, Zhou M, Huang Q, Mawlawi O, Dunner K Jr, Li C, Gupta S. Imaging Intratumoral Nanoparticle Uptake After Combining Nanoembolization with Various Ablative Therapies in Hepatic VX2 Rabbit Tumors. J Biomed Nanotechnol 2016;12:296-307. [PMID: 27305763 DOI: 10.1166/jbn.2016.2174] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
28 Choi JW, Park JH, Cho HR, Chung JW, Kim DD, Kim HC, Cho HJ. Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor. Sci Rep 2017;7:554. [PMID: 28373713 DOI: 10.1038/s41598-017-00709-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
29 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
30 Li MF, Leung HW, Chan AL, Wang SY. Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. Ther Clin Risk Manag. 2018;14:1157-1168. [PMID: 30013351 DOI: 10.2147/tcrm.s162898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. J Vasc Interv Radiol. 2018;29:540-549.e4. [PMID: 29477619 DOI: 10.1016/j.jvir.2017.11.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Tao CY, Shang J, Chen T, Yu D, Jiang YM, Liu D, Cheng GY, Xiao J, Zhao ZZ. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e15030. [PMID: 30946340 DOI: 10.1097/MD.0000000000015030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
33 Gao ZH, Bai DS, Jiang GQ, Jin SJ. Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma. World J Hepatol. 2015;7:40-43. [PMID: 25624995 DOI: 10.4254/wjh.v7.i1.40] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
34 Wang X, Zhang X, Huang X, Li Y, Wu M, Liu J. The drug–drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. Xenobiotica 2015;46:651-8. [DOI: 10.3109/00498254.2015.1109160] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
35 Zeng J, Lv L, Mei Z. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2016;40:688-97. [DOI: 10.1016/j.clinre.2016.04.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
36 Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT, Cheng HT, Zong DW, Jiang L, Li HL. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017;8:97613-22. [PMID: 29228637 DOI: 10.18632/oncotarget.18811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol. 2015;7:1184-1191. [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
38 Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study. J Cancer 2019;10:1189-96. [PMID: 30854128 DOI: 10.7150/jca.28994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
39 Saito K, Ledsam J, Sugimoto K, Sourbron S, Araki Y, Tokuuye K. DCE-MRI for Early Prediction of Response in Hepatocellular Carcinoma after TACE and Sorafenib Therapy: A Pilot Study. J Belg Soc Radiol 2018;102:40. [PMID: 30039052 DOI: 10.5334/jbsr.1278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Yan X, Qiu Y. Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett 2016;379:220-4. [PMID: 26282785 DOI: 10.1016/j.canlet.2015.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
41 Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the management of hepatocellular carcinoma. World J Clin Oncol. 2017;8:203-213. [PMID: 28638790 DOI: 10.5306/wjco.v8.i3.203] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
42 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
43 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 305] [Article Influence: 121.7] [Reference Citation Analysis]
44 Qi X, Zhao Y, Li H, Guo X, Han G. Management of hepatocellular carcinoma: an overview of major findings from meta-analyses. Oncotarget 2016;7:34703-51. [PMID: 27167195 DOI: 10.18632/oncotarget.9157] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
45 Chen QF, Wu PH, Huang T, Shen LJ, Huang ZL, Li W. Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e17460. [PMID: 31577775 DOI: 10.1097/md.0000000000017460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Ohki T, Kondo M, Karasawa Y, Kawamura S, Maeshima S, Kojima K, Seki M, Toda N, Shioda Y, Tagawa K. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 2017;34:1097-108. [PMID: 28389996 DOI: 10.1007/s12325-017-0524-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Wu J, Li A, Yang J, Lu Y, Li J. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients: a retrospective study. Onco Targets Ther 2017;10:2761-8. [PMID: 28603426 DOI: 10.2147/OTT.S131022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
48 Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol 2015;7:1412-20. [PMID: 26052386 DOI: 10.4254/wjh.v7.i10.1412] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
49 Abdelaziz AO, Nabeel MM, Elbaz TM, Shousha HI, Hassan EM, Mahmoud SH, Rashed NA, Ibrahim MM, Abdelmaksoud AH. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol. 2015;50:479-484. [PMID: 25592058 DOI: 10.3109/00365521.2014.1003397] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
50 Poursaid A, Jensen MM, Nourbakhsh I, Weisenberger M, Hellgeth JW, Sampath S, Cappello J, Ghandehari H. Silk-Elastinlike Protein Polymer Liquid Chemoembolic for Localized Release of Doxorubicin and Sorafenib. Mol Pharmaceutics 2016;13:2736-48. [DOI: 10.1021/acs.molpharmaceut.6b00325] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
51 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 11.7] [Reference Citation Analysis]
52 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
53 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
54 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015;7:566-74. [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
55 Ikegami T, Yoshizumi T, Kawasaki J, Shimagaki T, Uchiyama H, Soejima Y, Maehara Y. Hepatocellular carcinoma developed in a living donor after left lobe donation: a case for caution. Hepatol Res 2017;47:715-8. [PMID: 27488094 DOI: 10.1111/hepr.12786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Lee SW, Lee HL, Han NI, Jang JW, Bae SH, Choi JY, Yoon SK. Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. Cancer Chemother Pharmacol 2017;79:81-8. [PMID: 27913882 DOI: 10.1007/s00280-016-3202-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kalyan A, Nimeiri H, Kulik L. Systemic therapy of hepatocellular carcinoma: current and promising. Clin Liver Dis 2015;19:421-32. [PMID: 25921671 DOI: 10.1016/j.cld.2015.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
58 Thein HH, Qiao Y, Zaheen A, Jembere N, Sapisochin G, Chan KKW, Yoshida EM, Earle CC. Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS One 2017;12:e0185198. [PMID: 29016627 DOI: 10.1371/journal.pone.0185198] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]